| HS Code | 495650 |
| Productname | (1R,1'R)-2,2'-(3,11-Dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline)-dioxalate Pharma Grade API |
| Commonname | Atracurium dioxalate (proposed/alternative salt); standard marketed salt is atracurium besylate |
| Chemicalname | (1R,1'R)-2,2'-(3,11-dioxo-4,10-dioxatridecamethylene)bis(1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinolinium) dioxalate |
| Saltform | Dioxalate as named; standard marketed salt is besylate |
| Molecularformula | Atracurium cation C53H72N2O12; atracurium besylate C65H82N2O18S2 |
| Molecularweight | Atracurium cation approximately 929.2 g/mol; atracurium besylate approximately 1243.5 g/mol |
| Drugclass | Non-depolarizing neuromuscular blocker; bis-benzylisoquinolinium |
| Mechanismofaction | Competitive antagonism at nicotinic acetylcholine receptors at the motor endplate |
| Therapeuticuse | Skeletal muscle relaxation during surgery, endotracheal intubation, and mechanical ventilation |
| Appearance | White to off-white powder; injection is clear, colorless to slightly yellow solution |
| Solubility | Soluble in water and ethanol; practically insoluble in nonpolar organic solvents |
| Ph | Injection pH typically 3.2 to 3.7 |
| Shelflife | Typical unopened API 24-36 months; injection typically 24-36 months under labeled storage |
| Purity | Pharma grade, typically ≥98.0% |
| Grade | Pharma Grade API |
| Prescriptionstatus | Rx only for approved atracurium products |
| Atccode | M03AC04 |
| Proteinbinding | Approximately 82% |
| Metabolism | Hofmann elimination and plasma esterase hydrolysis |
| Halflife | Approximately 20-30 minutes |
| Excretion | Urine and bile |
| Onsetofaction | Intravenous onset typically 2-3 minutes |
| Durationofaction | Typically 20-35 minutes, dose-dependent |
| Bioavailability | 100% intravenous; negligible oral bioavailability |
| Pregnancycategory | US pregnancy category C for atracurium |
| Antidote | Neostigmine plus an anticholinergic such as glycopyrrolate or atropine |
| Monitoring | Neuromuscular function monitoring recommended |
| Contraindications | Hypersensitivity to atracurium or components |
| Warnings | Anaphylaxis, histamine release, prolonged neuromuscular blockade, and ICU-associated weakness |
| Packaging | API in double polyethylene bags inside fiber drums; injection in vials, ampoules, or prefilled syringes |
As an accredited (1R,1'R)-2,2'-(3,11-Dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquindline)-dioxalate Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive (1R,1'R)-2,2'-(3,11-Dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquindline)-dioxalate Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
